Medical Condition News

RSS

Amorfix Life Sciences achieves 100% specificity in using EP-vCJD Blood Screening Assay

Amorfix Life Sciences, a company focused on treatments and diagnostics for misfolded protein diseases, today announced it has achieved 100% specificity (no reproducible false positive results) upon testing 19,000 blood donations for variant Creutzfeldt-Jakob Disease ("vCJD") with the EP-vCJD(TM) Blood Screening Assay at l'Etablissement Français du Sang de Pyrénées Méditerrannée ("EFS-PM") in Montpellier, France.

29 Oct 2009

Positive results from Genta's Phase 3 trial of Genasense

Genta Incorporated today announced top-line results from AGENDA, the Company’s Phase 3 trial of Genasense® (oblimersen sodium) Injection in patients with advanced melanoma. AGENDA is a randomized, double-blind, placebo-controlled trial of dacarbazine administered with or without Genasense® in patients who have not previously received chemotherapy.

29 Oct 2009

Protox Therapeutics to present Phase 2 study data of PRX302 for benign prostatic hyperplasia

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced that detailed data from its open-label Phase 2 clinical study of PRX302 in patients with moderate to severe benign prostatic hyperplasia (BPH) will be presented at the 30th World Congress of the Société Internationale d'Urologie Conference.

29 Oct 2009

Seminar on multiple myeloma

MediCom Worldwide, Inc., an accredited provider of continuing medical education for physicians, pharmacists, and nurses, announces a Friday Satellite Symposium on Multiple Myeloma Preceding the 51st ASH Annual Meeting entitled Unifying Practice Patterns Among Academic and Community Clinicians: Focus on Myeloma.

29 Oct 2009

Publix Supermarkets to sell HeartSavior and LipidShield Plus

New Health Corp. is proud to announce that HeartSavior(TM) and LipidShield® Plus are now available at Publix Supermarkets.

29 Oct 2009

Grassroots Health and the University of Toronto School of Medicine to host a Vitamin D symposium

Vitamin D Deficiency - linked to significantly higher rates of most cancers, heart disease, autoimmune diseases such as multiple sclerosis, and even flu - affects 97 per cent of Canadians. Yet fewer than 3 per cent of Canadians say they know their vitamin D blood levels.

29 Oct 2009

Non-surgical alternative treatment for moderate to advanced gum disease announced

BIOLASE Technology, Inc. today announced its new Deep Pocket Therapy with New Attachment™ using the Waterlase MD™ and patented Radial Firing Perio Tips™ (RFPT) for a non-surgical alternative treatment for moderate to advanced gum disease.

29 Oct 2009

Fondation Jacques-F. Gougoux donates over $57,000 to the Quebec Division of the Multiple Sclerosis Society

The Quebec Division of the Multiple Sclerosis Society of Canada is delighted to be able to count on the Fondation Jacques-F. Gougoux in improving the quality of life for people with multiple sclerosis and their families. A donation of $57,386, spread over 15 years, will enable the MS Society to make some of its services more accessible.

29 Oct 2009

Raise awareness about psoriasis: National Psoriasis Foundation's call to psoriasis affected Americans

Today is World Psoriasis Day and the National Psoriasis Foundation is asking all Americans affected by psoriasis and psoriatic arthritis to raise awareness about these diseases by going to www.psoriasis.org/wpd and taking action.

29 Oct 2009

CytRx study reveals potential of molecular chaperones in design of anti-aging pharmaceuticals

CytRx Corporation, a biopharmaceutical company and a leader in molecular chaperone regulation technology, today announced that a paper published in the peer-reviewed journal Gerontology concluded that molecular chaperone amplification may represent a “significant strategy” in the future design of anti-aging pharmaceuticals.

29 Oct 2009

PFNC presents Wake Forest psychiatrist the Eugene A. Hargrove, M.D., Award

Vaughn McCall, M.D., M.S., chair of Psychiatry and Behavioral Medicine at Wake Forest University Baptist Medical Center, has been presented the Eugene A. Hargrove, M.D., Award by the Psychiatric Foundation of North Carolina (PFNC).

29 Oct 2009

Effects of head injuries on players in the NFL: House Judiciary Committee's call to experts

The House Judiciary Committee today called upon national experts and stakeholders in the fields of science and sport to better understand the effects of head injuries on players in the National Football League (NFL). Nationally recognized sports physician and neurosurgeon, Julian E. Bailes, M.D. was called to provide expert testimony based on decades of research detailing how repetitive head trauma on the field leads to long-term neurological damage among athletes.

29 Oct 2009

Highlights of new cancer research to be presented at 51st ASTRO Annual Meeting

The following are highlights of new cancer research being presented at the American Society for Radiation Oncology's (ASTRO) 51st Annual Meeting on November 1-5, 2009, in Chicago.

29 Oct 2009

Long-term effects of statin therapy could lead to transient or permanent cognitive impairment

Besides their tremendous value in treating high cholesterol and lowering the risk of heart disease, statins have also been reported to potentially lower the risks of other diseases, such as dementia. However, a study in the October Journal of Lipid Research finds that similar statin drugs can have profoundly different effects on brain cells -both beneficial and detrimental.

29 Oct 2009

National study to prevent strokes in children and adolescents with sickle cell anemia

St. Jude Children's Research Hospital investigators were recently awarded a $23 million federal grant to launch a national study of the drug hydroxyurea to prevent first strokes in children and adolescents with sickle cell anemia (SCA).

29 Oct 2009

CHS, BPC and CHEP integrated into one hypertension entity

The Heart and Stroke Foundation of Canada today welcomed the integration of the Canadian Hypertension Society (CHS), Blood Pressure Canada (BPC), and the Canadian Hypertension Education Program (CHEP) into one hypertension entity.

29 Oct 2009

CTE cases are misdiagnosed as Alzheimer's disease, says CSTE researchers

The Center for the Study of Traumatic Encephalopathy (CSTE) at Boston University School of Medicine (BUSM) announced today that a recently deceased member of the NFL Hall of Fame suffered from the degenerative brain disease Chronic Traumatic Encephalopathy (CTE) when he died, becoming the 10th former NFL player diagnosed with the disease.

29 Oct 2009

CIRM awards Salk Institute $10.8M grant to develop stem-cell based therapy for Lou Gehrig's Disease

The Salk Institute has been awarded a $10.8 million grant by the California Institute for Regenerative Medicine (CIRM) for translational research focusing on developing a novel stem-cell based therapy for Amyotrophic Lateral Sclerosis (ALS) - or Lou Gehrig's Disease.

29 Oct 2009

FDA Anesthesiology and Respiratory Therapy Devices Panel recommends approval for Asthmatx' Alair System

Asthmatx Inc., announced today that the Anesthesiology and Respiratory Therapy Devices Panel of the Medical Devices Advisory Committee to the U.S. Food and Drug Administration (FDA) voted to recommend that the Alair® System, a device utilized in bronchial thermoplasty for the treatment of severe persistent asthma in patients 18 years and older, be found approvable with conditions.

29 Oct 2009

Study: Short-term use of COX-2 inhibitors may help prevent gastric cancer

Elevated expression of COX-2 is observed in a wide variety of human malignancies, including gastric cancer. Long-term high dose COX-2 inhibitors can inhibit gastric carcinogenesis in animal models, but the possible life-threatening cardiovascular adverse events limit its popular application. Therefore, it is important to evaluate the optimal intervention point of COX-2 inhibitors for inhibiting H. pylori-associated gastric carcinogenesis.

29 Oct 2009

Medical Condition News

Amorfix Life Sciences achieves 100% specificity in using EP-vCJD Blood Screening Assay

Positive results from Genta's Phase 3 trial of Genasense

Protox Therapeutics to present Phase 2 study data of PRX302 for benign prostatic hyperplasia

Seminar on multiple myeloma

Publix Supermarkets to sell HeartSavior and LipidShield Plus

Grassroots Health and the University of Toronto School of Medicine to host a Vitamin D symposium

Non-surgical alternative treatment for moderate to advanced gum disease announced

Fondation Jacques-F. Gougoux donates over $57,000 to the Quebec Division of the Multiple Sclerosis Society

Raise awareness about psoriasis: National Psoriasis Foundation's call to psoriasis affected Americans

CytRx study reveals potential of molecular chaperones in design of anti-aging pharmaceuticals

PFNC presents Wake Forest psychiatrist the Eugene A. Hargrove, M.D., Award

Effects of head injuries on players in the NFL: House Judiciary Committee's call to experts

Highlights of new cancer research to be presented at 51st ASTRO Annual Meeting

Long-term effects of statin therapy could lead to transient or permanent cognitive impairment

National study to prevent strokes in children and adolescents with sickle cell anemia

CHS, BPC and CHEP integrated into one hypertension entity

CTE cases are misdiagnosed as Alzheimer's disease, says CSTE researchers

CIRM awards Salk Institute $10.8M grant to develop stem-cell based therapy for Lou Gehrig's Disease

FDA Anesthesiology and Respiratory Therapy Devices Panel recommends approval for Asthmatx' Alair System

Study: Short-term use of COX-2 inhibitors may help prevent gastric cancer

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News